

<b>Case Number:</b>	CM14-0152697		
<b>Date Assigned:</b>	09/22/2014	<b>Date of Injury:</b>	09/27/2011
<b>Decision Date:</b>	10/22/2014	<b>UR Denial Date:</b>	09/08/2014
<b>Priority:</b>	Standard	<b>Application Received:</b>	09/18/2014

### HOW THE IMR FINAL DETERMINATION WAS MADE

MAXIMUS Federal Services sent the complete case file to an expert reviewer. He/she has no affiliation with the employer, employee, providers or the claims administrator. The expert reviewer is Board Certified in Preventive Medicine and is licensed to practice in California. He/she has been in active clinical practice for more than five years and is currently working at least 24 hours a week in active practice. The expert reviewer was selected based on his/her clinical experience, education, background, and expertise in the same or similar specialties that evaluate and/or treat the medical condition and disputed items/services. He/she is familiar with governing laws and regulations, including the strength of evidence hierarchy that applies to Independent Medical Review determinations.

### CLINICAL CASE SUMMARY

The expert reviewer developed the following clinical case summary based on a review of the case file, including all medical records:

According to the records made available for review, this is a 49-year-old male with a 9/27/11 date of injury. At the time (7/17/14) of request for authorization for Ketoprofen 100% (Gabapentin/Ketoprofen/Lidocaine/Lidoderm), there is documentation of subjective (pain and discomfort of the left foot and right shoulder) and objective (tenderness to palpation over the right shoulder with decreased range of motion; positive Apley's test of the left knee; and mildly decreased strength of the right shoulder and left knee) findings, current diagnoses (right shoulder rotator cuff injury, right shoulder internal derangement, left foot internal derangement, left shoulder sprain/strain, myofascial pain syndrome, left ankle internal derangement, and right shoulder sprain/strain), and treatment to date (medications (including opioids and topical creams).

### IMR ISSUES, DECISIONS AND RATIONALES

The Final Determination was based on decisions for the disputed items/services set forth below:

**Ketoprofen 100% (Gabapentin/Ketoprofen/Lidocaine/Lidoderm): Upheld**

**Claims Administrator guideline:** Decision based on MTUS Chronic Pain Treatment Guidelines.

**MAXIMUS guideline:** Decision based on MTUS Chronic Pain Treatment Guidelines Topical Analgesics Page(s): 111-113.

**Decision rationale:** Chronic Pain Medical Treatment Guidelines identifies that many agents are compounded as monotherapy or in combination for pain control; that Ketoprofen, Lidocaine (in creams, lotion or gels), Capsaicin in a 0.0375% formulation, Baclofen and other muscle relaxants, and Gabapentin and other anti-epilepsy drugs are not recommended for topical applications; and that any compounded product that contains at least one drug (or drug class) that is not recommended, is not recommended. Within the medical information available for review, there is documentation of diagnoses of status post revision lumbar fusion, status post previous lumbar fusion, lumbar discogenic disease, possible early sacroiliac joint dysfunction, cervical strain, and cervical spine degenerative disc disease. However, the requested compounded medication consists of at least one drug (Ketoprofen, Lidocaine. and Gabapentin) that is not recommended. Therefore, based on guidelines and a review of the evidence, the request for Ketoprofen 100% (Gabapentin/Ketoprofen/Lidocaine/Lidoderm) is not medically necessary.